Clinical trial
Non-small Cell Lung Cancer Study US75 (Z-PACT)
NCT00086268 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00086268 |
|---|---|
| Title | Non-small Cell Lung Cancer Study US75 (Z-PACT) |
| Acronym | ZPACT |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non Small Cell Lung Carcinoma |
| Intervention type | Drug |
| Interventions | zoledronic acid, Taxotere, Carboplatin |
| Enrollment | 250 |
| Start date | Apr 1, 2004 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Jul 1, 2004 |
| Last update posted | Sep 13, 2017 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: